Novartis Psoriasis Drug Shows High Results First Time in China

| By | China, Clinical Study, Novartis, psoriasis
0
130

Results strengthen unique position of Cosentyx as a rapid and long-lasting complete treatment of psoriatic disease, with over 200,000 patients treated worldwide.

Novartis announced today new data in 441 Chinese patients with moderate to severe plaque psoriasis from a Phase III study investigating the efficacy and safety of Cosentyx (secukinumab). The data, part of a broader ongoing 52 week Phase III study in 543 patients, show 97.7% of patients treated with Cosentyx 300mg achieved PASI 75 and 80.9% achieved PASI 90 by week 12, with 87% of patients reaching PASI 90 by week 16. In patients treated with Cosentyx 150mg, 87.8% achieved PASI 75 and 66.4% achieved PASI 90 at week 12.

Cosentyx continues to deliver what psoriasis patients need – reimagining care to provide clear skin and a complete treatment. We’re excited to report for the first time data for a Chinese population, and to see strong support from the data for Cosentyx,

said Eric Hughes,
Global Development Unit Head,
Immunology, Hepatology and Dermatology,
and China Region Development Head.

Cosentyx is backed by a wealth of research with 100 studies and has been proven to offer clear or almost clear skin in 8 out of 10 patients within 16 weeks of treatment. Nearly 100% of response rates are maintained up to 5 years. It is a fully human monoclonal antibody neutralizing IL-17A and has demonstrated rapid, long-lasting efficacy and safety in the treatment of moderate to severe psoriasis, psoriatic arthritis, and the more persistent manifestations of psoriasis, namely scalp, palms, soles and nails

SOURCE: novartis
SHARE
GMP news
Pharmaceutical industry News and events. Technology transfer and contract manufacturing of medicines.